<DOC>
	<DOCNO>NCT01370499</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability LY2216684 administer daily adjunctive treatment Selective Serotonin Reuptake Inhibitors ( SSRI ) approximately 1 year patient Major Depressive Disorder ( MDD ) partial responder SSRI treatment .</brief_summary>
	<brief_title>A Study LY2216684 Patients With Major Depression Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Participants must complete Study LNBM : NCT01173601 Study LNBQ : NCT01187407 Participants must competent able give inform consent Participants currently additional ongoing Diagnostic Statistical Manual Mental Disorder , fourth edition , text revision ( DSMIVTR ) Axis I condition major depression consider primary diagnosis within 1 year enter trial Participants anxiety disorder consider primary diagnosis within past year Participants current previous diagnosis bipolar disorder , schizophrenia , psychotic disorder Participants history substance abuse within past 1 year , and/or substance dependence within past 1 year , include caffeine nicotine Participants Axis II disorder , judgment investigator , would interfere compliance study Participants lack full response current depressive episode 2 adequate course antidepressant therapy clinically appropriate dose least 4 week , judgment investigator , patient treatmentresistant depression Participants history electroconvulsive therapy ( ECT ) , transcranial magnetic stimulation ( TMS ) , psychosurgery within last year Participants woman pregnant breastfeeding Participants , opinion investigator , judge serious risk harm self others Participants serious unstable medical illness Participants diagnose medical condition could exacerbate noradrenergic agent Participants history severe allergies 1 class medication multiple adverse drug reaction Participants history seizure disorder ( febrile seizure ) Participants receive treatment monoamine oxidase inhibitor ( MAOI ) within 14 day prior enter trial potential need use MAOI within 3 day discontinuation study Participants require psychotropic medication sedative/hypnotic medication sleep Participants take received treatment exclude medication within 7 day prior enter trial Participants thyroid stimulate hormone ( TSH ) level outside laboratory establish reference range . Participants previously diagnose hyperthyroidism hypothyroidism treat stable dose thyroid supplement least past 3 month , clinically chemically euthyroid allow participate study . Participants initiate discontinue hormone therapy within previous 3 month prior enrollment Participants initiate psychotherapy , change intensity psychotherapy nondrug therapy ( acupuncture hypnosis ) within 6 week prior enrollment time stud . Participants positive urine drug screen ( UDS ) substances abuse enter trial Participants significantly violate rule patient must comply Study LNBM Study LNBQ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>